Back to search

United Kingdom· GB-APID-42575711000001100

Tepkinly 48mg/0.8ml solution for injection vials

A epcoritamab product containing epcoritamab, registered in United Kingdom by AbbVie Ltd. The same ATC class is registered in 14 of our 19 countries.

ATC L01FX27

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedTepkinly 48mg/0.8ml solution for inje…ATCL01FX27REGISTER NO.GB-APID-4257571100000…PACKS LISTED1CHECKEDSeptember 13, 2026

Where it is registered

Epcoritamab is registered in 14 of 19 countries.

Countries holding a registration under ATC L01FX27 (epcoritamab), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 9 of them publish a price we can compare per daily dose

Epcoritamab · ATC L01FX27

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of epcoritamab costs, country by country.

Normalised to the WHO defined daily dose (1.7 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Epcoritamab · price per daily dose (1.7 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$281.38
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Epcoritamab
Manufacturer
AbbVie Ltd
Country
United Kingdom (GB)
ATC code
L01FX27
ATC class
Epcoritamab
Defined daily dose
1.7 mg, P
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 1

  • gtin
    08054083026374

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Epcoritamab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All epcoritamab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Tepkinly
  • Liechtenstein · Tepkinly
  • Norway · Tepkinly

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/126c68e6-abe3-497b-9e61-4b3aa46cfd6b
GET /v1/drugs/126c68e6-abe3-497b-9e61-4b3aa46cfd6b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "42575711000001100",
  "desc": "Tepkinly 48mg/0.8ml solution for injection vials (AbbVie Ltd)",
  "form": "Solution for injection",
  "vpid": "42577911000001108",
  "source": "dmd",
  "vtm_id": "42577111000001105",
  "strength": "60 mg",
  "substance": "Epcoritamab",
  "ingredient": "Epcoritamab",
  "supplier_code": "20741511000001103"
}

See everything about epcoritamab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.